Abstract:Background: Dysregulation of clusterin (CLU) and over-activated complement C5 were involved in the development and progression of lupus nephritis (LN). Allogeneic mesenchymal stem cells (MSCs) transplantation has achieved good clinical efficacy for refractory LN, however, the exact mechanisms remain to be elucidated. Objectives: To investigate the clinical effect of MSCs on SLE model mice (B6.lpr), and explore the mechanisms of MSCs inhibiting the activated complement C5 in vivo and in vitro. Methods: 26-week-old female B6.lpr mice were randomly allocated in three groups, which were given the following treatments, CTX (200mg/kg), MSCs (1 x 106), and an equal volume of PBS. 24 hours urine and peripheral blood were collected periodically. All mice were sacrificed at 40 weeks of age. Urine protein to creatinine ratio and plasma creatinine were quantified to evaluate renal disease. Levels of C3, soluble C5b-9 (SC5b-9), CLU, and anti-dsDNA antibody were determined in the plasma by ELISA. Histopathological evaluation of renal lesions was undertaken by HE, PAS, PASM and Masson staining under light microscopy. Podocyte foot processes were assayed by the transmission electron microscopy. Accumulation of immunocomplexes (IC), C3, C5b-9, and CLU were detected in renal specimens by immunofluorescence or immunohistochemistry. Expressions of CLU in MSCs were detected by real-time PCR and ELISA. MSCs-derived CLU was purified and functional analysis was performed accordingly. Results: Compared to the control mice, both proteinuria and plasma creatinine were significantly improved in each treatment group. Plasma C3 was significantly elevated in mice of MSCs and CTX groups. There were decline trends in plasma levels of anti-dsDNA and SC5b-9 in treated mice when compared to the control mice. Notably, plasma CLU was only significantly elevated in MSCs treated mice. Pathological analysis showed that the proliferation of glomerular cells and foot process fusion were significantly alleviated in MSCs treated mice. Immunofluorescence and immunohistochemistry showed that depositions of IC, C1q, C3 and C5b-9 were significantly decreased in the MSCs group, although the expression of CLU was obviously increased in these mice. Mechanistically, interferon-α promoted the secretion of functional CLU by MSCs in vitro. Conclusion: Allogeneic MSCs transplantation can effectively improve the clinical outcome of lupus mice. Possible mechanisms of MSCs might be related to inhibit the activated C5 via clusterin, which would be a potential treatment target in the future. Reference [1] Harris CL, et al. Mol Immunol. 2018 Disclosure of Interests: None declared

Administration of Activated Lymphocyte-Derived DNA Accelerates and Aggravates Lupus Nephritis in B6/lpr Mice: a New Approach to Modify a Lupus Murine Model.

Dependence of Glomerulonephritis Induction on Novel Intraglomerular Alternatively Activated Bone Marrow–Derived Macrophages and Mac-1 and PD-L1 in Lupus-Prone NZM2328 Mice

Anti-DNA Antibody-Targeted D-peptide Nanoparticles Ameliorate Lupus Nephritis in MRL/lpr Mice

Genetic approach to study lupus glomerulonephritis.

Novel Mitophagy Inducer Alleviates Lupus Nephritis by Reducing Myeloid Cell Activation and Autoantigen Presentation.

Interleukin-22 From Type 3 Innate Lymphoid Cells Aggravates Lupus Nephritis by Promoting Macrophage Infiltration in Lupus-Prone Mice

Induction of Systemic Lupus Erythematosus-Like Syndrome in Syngeneic Mice by Immunization with Activated Lymphocyte-Derived DNA

Lipocalin-2 Exacerbates Lupus Nephritis by Promoting Th1 Cell Differentiation

AB0045 MESENCHYMAL STEM CELLS INHIBIT THE ACTIVATED COMPLEMENT C5 BY CLUSTERIN IN LUPUS NEPHRITIS

Mannose-Binding Lectin Blunts Macrophage Polarization and Ameliorates Lupus Nephritis

Correction: Abrogation of Lupus Nephritis in Somatic Hypermutation–Deficient B6.MRL-Faslpr Mice/j Mice

Amelioration of Lupus Nephritis by Serum Amyloid P Component Gene Therapy with Distinct Mechanisms Varied from Different Stage of the Disease

Treatment with lysophosphatidic acid improves glomerulonephritis through the suppression of macrophage activation in a murine model of systemic lupus erythematosus

Demethylzeylasteral ameliorates podocyte damage in murine lupus by inhibiting inflammation and enhancing autophagy

Allogenic mesenchymal stem cell transplantation ameliorates nephritis in lupus mice via inhibition of B-cell activation

Blockade of TLR9 Signaling in B Cells Impaired Anti-Dsdna Antibody Production in Mice Induced by Activated Syngenic Lymphocyte-Derived DNA Immunization

5-aminolevulinic acid combined with sodium ferrous citrate ameliorated lupus nephritis in a mouse chronic graft-versus-host disease model

Self DNA from Lymphocytes That Have Undergone Activation-Induced Cell Death Enhances Murine B Cell Proliferation and Antibody Production.

Therapeutic Effect of Leflunomide on the Development of Experimental Lupus Nephritis in Mice

miR‑146a‑5p protects against renal injury in MRL/lpr mice via improvement of the Treg/Th17 imbalance by targeting the TRAF6/NF‑κB axis

Ac-SDKP ameliorates the progression of lupus nephritis in MRL/lpr mice.